Neurocrine to buy Soleno Therapeutics for $2.9 billion
- Postato il 6 aprile 2026
- Di CNBC
- 0 Visualizzazioni
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.